{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:30:57Z","timestamp":1791549057323,"version":"4.3.4"},"reference-count":80,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T00:00:00Z","timestamp":1708214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T00:00:00Z","timestamp":1708214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current hemophilia B treatment guidelines recommend routine prophylaxis with factor IX (FIX) replacement products, tailored to maintain plasma activity at levels that will prevent bleeds. However, plasma FIX activity may not be the primary determinant or best indicator of hemostatic efficacy due to its extravascular distribution. FIX replacement therapy has evolved to include extended half\u2010life (EHL) products that provide effective bleed protection when administered at intervals of 7\u2009days or longer. rFIXFc is a recombinant fusion protein with an extended circulation time. rFIXFc has a biodistribution profile consistent with distribution into extravascular space, where it may support hemostasis at sites of vessel injury independent of circulating plasma activity levels. The safety and efficacy of rFIXFc prophylaxis is well established in adults, adolescents and children including previously untreated patients with hemophilia B, with substantial evidence from clinical trials and real\u2010world clinical practice. This review describes the pharmacokinetic characteristics of rFIXFc, summarizes available safety and efficacy data, and evaluates the use of rFIXFc in special populations. Current hemophilia B treatment challenges, including target FIX plasma levels, perioperative use, and management of patients with comorbidities, are discussed together with the potential role of EHL products in the future treatment landscape of hemophilia B.<\/jats:p>","DOI":"10.1111\/ejh.14176","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T02:40:55Z","timestamp":1708310455000},"page":"678-691","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recombinant factor\n                    <scp>IX Fc<\/scp>\n                    for the treatment of hemophilia B"],"prefix":"10.1111","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-8747","authenticated-orcid":false,"given":"Rolf","family":"Ljung","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences\u2014Pediatrics Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-4074","authenticated-orcid":false,"given":"Davide","family":"Matino","sequence":"additional","affiliation":[{"name":"Department of Medicine McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-7159","authenticated-orcid":false,"given":"Amy D.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Indiana Hemophilia &amp; Thrombosis Center, Inc  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,18]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221085202"},{"key":"e_1_2_16_4_1","unstructured":"Pfizer Inc.BeneFIX prescribing information.2020Accessed September 1 2023.https:\/\/www.fda.gov\/media\/73556\/download"},{"key":"e_1_2_16_5_1","unstructured":"Corporation BH.RIXUBIS prescribing information.2014Accessed September 1 2023.https:\/\/www.fda.gov\/media\/86123\/download"},{"key":"e_1_2_16_6_1","unstructured":"LLC AB.IXINITY prescribing information.2021Accessed September 1 2023.https:\/\/www.fda.gov\/media\/91715\/download"},{"key":"e_1_2_16_7_1","unstructured":"A\/S NN.Refixia summary of product characteristics.2022Accessed September 1 2023.https:\/\/www.medicines.org.uk\/emc\/product\/9445\/smpc"},{"key":"e_1_2_16_8_1","unstructured":"Novo Nordisk Inc.REBINYN prescribing information.2017Accessed September 1 2023.https:\/\/www.fda.gov\/media\/105491\/download"},{"key":"e_1_2_16_9_1","unstructured":"LLC CB.IDELVION prescribing information.2021Accessed September 1 2023.https:\/\/www.fda.gov\/media\/96526\/download"},{"key":"e_1_2_16_10_1","unstructured":"Inc BT.ALPROLIX prescribing information.2020Accessed September 1 2023.https:\/\/www.fda.gov\/media\/88119\/download"},{"key":"e_1_2_16_11_1","unstructured":"Swedish Orphan Biovitrum Ltd.ALPROLIX 250 IU powder and solvent for solution for injection \u2013 summary of product characteristics.2021Accessed September 1 2023.https:\/\/www.medicines.org.uk\/emc\/product\/7277\/smpc#gref"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14152"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12163"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12451"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367003"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30193-4"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_2_16_18_1","unstructured":"Corporation BH.ADVATE prescribing information.2011Accessed May 8 2023.https:\/\/www.fda.gov\/media\/70008\/download"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12216"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15552"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0129-7"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-12-0942"},{"key":"e_1_2_16_23_1","first-page":"1061","article-title":"Extravascular distribution of conventional and ehl FIX products using in vivo SPECT imaging analysis in hemophilia B mice","volume":"130","author":"Salas J","year":"2017","journal-title":"Blood"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14300"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-696104"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12421"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966888"},{"key":"e_1_2_16_28_1","first-page":"24","article-title":"Distribution of rFIXFc and FIX using in vivo PET imaging analysis in non\u2010human primates","volume":"24","author":"Salas J","year":"2018","journal-title":"Haemophilia"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126196"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13943"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13896"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884015"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14727"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14036"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004085"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S312885"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1620246"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010023\u201002559\u20101"},{"key":"e_1_2_16_39_1","first-page":"57","article-title":"Final data from B\u2010SURE, a French multicentre study in patients with haemophilia B, evaluating real\u2010world usage and effectiveness of recombinant factor IX Fc (rFIXFc)","volume":"29","author":"Chambost H","year":"2023","journal-title":"Haemophilia"},{"key":"e_1_2_16_40_1","first-page":"48","article-title":"Final data from the PREVENT study evaluating real\u2010world usage and effectiveness of a recombinant factor VIII Fc and recombinant factor IX Fc in haemophilia A or B in Germany","volume":"29","author":"Bidlingmaier C","year":"2023","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_16_41_1","article-title":"Interim analysis from B\u2010MORE, a 24\u2010month prospective, multicentre, non\u2010interventional study on effectiveness and usage of recombinant factor IX Fc (rFIXFc) in haemophilia B [ISTH abstract PB1153]","volume":"6","author":"Glosli H","year":"2022","journal-title":"Presented at: ISTH Congress 2022; Res Pract Thromb Haemost"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1991901"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13970"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14307"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12602"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13109"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14369"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12601"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.17212"},{"key":"e_1_2_16_50_1","first-page":"27","article-title":"Real\u2010world experience of switching from SHL\u2010rFIX to EHL\u2010rFIXFc in moderate and severe haemophilia B patients: a retrospective analysis from two belgian centers","author":"Peerlinck K","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_16_51_1","article-title":"A within\u2010patient comparison of efficacy and outcome of recombinant FIX in haemophilia B in the UK [EAHAD 2020 P074]","volume":"26","author":"Wall C","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_16_52_1","first-page":"e12788","article-title":"Norwegian real\u2010world experience with recombinant factor IX Fc (rFIXFc) in haemophilia B (HB) patients [ISTH abstract PB1175]","volume":"6","author":"Holme P","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_16_53_1","article-title":"First interim analysis of a 24\u2010month French, multicentre, prospective, non\u2010interventional study evaluating the real\u2010world usage and effectiveness of the extended half\u2010life recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B (B\u2010SURE) [ISTH abstract OC 08.1]. Presented at: ISTH Congress 2021;","volume":"5","author":"Chambost H","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_16_54_1","unstructured":"TraetsMJM FischerK UitslagerN et al.Transition from standard half\u2010life to extended half\u2010life products in patients with haemophilia A and B: a single center experience [ISTH abstract 1442]. Presented at ISTH Congress 2019;Res Pract Thromb Haemost.2019;3(S1).https:\/\/academy.isth.org\/isth\/2019\/melbourne\/264632\/marissa.traets.transition.from.standard.half\u2010life.to.extended.half\u2010life.html"},{"key":"e_1_2_16_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13432"},{"issue":"2","key":"e_1_2_16_56_1","article-title":"Real\u2010life experience in switching to a new extended half\u2010life product at a portugese haemophilia centre: first impressions and estimated results [EAHAD 2021 abstract 173]","volume":"27","author":"Catarino C","year":"2021","journal-title":"Haemophilia"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14704"},{"key":"e_1_2_16_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14198"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1160\/th13-11-0971"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13189"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02300-1"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14114"},{"key":"e_1_2_16_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12760"},{"issue":"2","key":"e_1_2_16_64_1","article-title":"Real\u2010world effectiveness and usage of recombinant factor IX Fc fusion protein (rFIXFc) for management of major\/minor surgeries in patients with haemophilia B in France: results from the ongoing B\u2010SURE study [EAHAD abstract 175]","volume":"27","author":"Castet S","year":"2021","journal-title":"Haemophilia"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14426"},{"key":"e_1_2_16_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14585"},{"issue":"2","key":"e_1_2_16_67_1","first-page":"e12589","article-title":"Extended half\u2010life products for perioperative hemostasis in major orthopedic surgery: real\u2010world data from the LASH study","volume":"5","author":"Solimeno LP","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5848"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221104595"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2021.9169"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2450"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12437"},{"key":"e_1_2_16_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14201"},{"key":"e_1_2_16_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14675"},{"key":"e_1_2_16_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.442"},{"key":"e_1_2_16_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159631"},{"key":"e_1_2_16_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310766"},{"key":"e_1_2_16_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2133492"},{"key":"e_1_2_16_79_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.169"},{"key":"e_1_2_16_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_2_16_81_1","unstructured":"ClinicalTrials.gov.2023. Accessed September 1 2023.www.clinicaltrials.gov"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.14176","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:58:29Z","timestamp":1772960309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,18]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/ejh.14176"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14176","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,18]]},"assertion":[{"value":"2023-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}